Metformin Therapy Changes Gut Microbiota Alpha-Diversity in COVID-19 Patients with Type 2 Diabetes: The Role of SARS-CoV-2 Variants and Antibiotic Treatment
dc.contributor.author | Petakh, Pavlo | |
dc.contributor.author | Kamyshna, Iryna | |
dc.contributor.author | Oksenych, Valentyn | |
dc.contributor.author | Kainov, Denis | |
dc.contributor.author | Kamyshnyi, Aleksandr | |
dc.date.accessioned | 2023-11-17T11:02:57Z | |
dc.date.available | 2023-11-17T11:02:57Z | |
dc.date.created | 2023-06-20T10:32:11Z | |
dc.date.issued | 2023 | |
dc.identifier.citation | Pharmaceuticals. 2023, 16 (6), . | en_US |
dc.identifier.issn | 1424-8247 | |
dc.identifier.uri | https://hdl.handle.net/11250/3103181 | |
dc.description.abstract | The gut microbiota play a crucial role in maintaining host health and have a significant impact on human health and disease. In this study, we investigated the alpha diversity of gut microbiota in COVID-19 patients and analyzed the impact of COVID-19 variants, antibiotic treatment, type 2 diabetes (T2D), and metformin therapy on gut microbiota composition and diversity. We used a culture-based method to analyze the gut microbiota and calculated alpha-diversity using the Shannon H′ and Simpson 1/D indices. We collected clinical data, such as the length of hospital stay (LoS), C-reactive protein (CRP) levels, and neutrophil-to-lymphocyte ratio. We found that patients with T2D had significantly lower alpha-diversity than those without T2D. Antibiotic use was associated with a reduction in alpha-diversity, while metformin therapy was associated with an increase. We did not find significant differences in alpha-diversity between the Delta and Omicron groups. The length of hospital stay, CRP levels, and NLR showed weak to moderate correlations with alpha diversity. Our findings suggest that maintaining a diverse gut microbiota may benefit COVID-19 patients with T2D. Interventions to preserve or restore gut microbiota diversity, such as avoiding unnecessary antibiotic use, promoting metformin therapy, and incorporating probiotics, may improve patient outcomes. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | MDPI | en_US |
dc.rights | Navngivelse 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/deed.no | * |
dc.title | Metformin Therapy Changes Gut Microbiota Alpha-Diversity in COVID-19 Patients with Type 2 Diabetes: The Role of SARS-CoV-2 Variants and Antibiotic Treatment | en_US |
dc.title.alternative | Metformin Therapy Changes Gut Microbiota Alpha-Diversity in COVID-19 Patients with Type 2 Diabetes: The Role of SARS-CoV-2 Variants and Antibiotic Treatment | en_US |
dc.type | Peer reviewed | en_US |
dc.type | Journal article | en_US |
dc.description.version | publishedVersion | en_US |
dc.source.pagenumber | 14 | en_US |
dc.source.volume | 16 | en_US |
dc.source.journal | Pharmaceuticals | en_US |
dc.source.issue | 6 | en_US |
dc.identifier.doi | 10.3390/ph16060904 | |
dc.identifier.cristin | 2156099 | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 |